Merck Defeats Mylan's Challenge To Zetia, Vytorin Patent

Law360, New York (April 27, 2012, 8:59 PM EDT) -- A Merck & Co. Inc. unit prevailed Friday in a patent suit against Mylan Pharmaceuticals Inc. over its generic versions of cholesterol drugs Zetia and Vytorin, with a New Jersey federal judge ruling valid Merck's patent on an active ingredient of the drugs.

Mylan had already conceded that if the patent belonging to Merck unit Schering-Plough Corp. was valid and enforceable, its generics infringed, and the court issued an injunction barring approval of the generic drugs until the patent expires, according to Merck.

“The court appropriately...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.